Project Grant R44AI117976

The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...

The federal Project Grant award R44AI186932 for $300,000 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports the development of an "Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens" by Orlance, Inc., a woman-owned small business. The project aims to combine the advantages of a closely matched seasonal influenza DNA vaccine with a...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $1,082,429 Cooperative Agreement to Duke University to develop computational models that predict the sequences of antibody archetypes generated in response to influenza proteins and simulate how a polyclonal antibody response protects against influenza infection. The research aims to address the challenges of seasonal influenza vaccines, which have only 10-60% effectiveness, and the potential for devastating...

This $586,250 Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to investigate how distinct age-associated B cell subsets can protect the aged population from influenza. The primary focus is on understanding the potential of "age-associated B cells" (ABC) to respond to influenza infection and generate antibody-secreting cells, B...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $709,236 to support research aimed at overcoming immunodominance to enable the development of universal influenza vaccines. The primary goal is to gain mechanistic insights into how adjuvant formulation influences B cell intrinsic and extrinsic factors that shape immunodominance and the breadth of humoral responses....

This $682,008 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to advance the development of monoclonal antibody (mAb) therapeutics for the treatment of paramyxovirus infections, with a specific focus on parainfluenza virus (PIV). The key objectives are to: 1) define the human B cell repertoire to the PIV fusion (F) and hemagglutinin-neuraminidase (HN) surface proteins, 2)...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 project grant (R21AI185735) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant supports research focused on developing a broad-spectrum influenza vaccine by targeting the neuraminidase (NA) protein. Specifically, the project aims to evaluate recently discovered NA broadly neutralizing antibodies (bnAbs) to assess their potential for...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,195,056 to Vanderbilt University to develop and implement computational tools to design broadly protective influenza vaccines. The project aims to leverage machine learning and artificial intelligence to create innovative immunogen candidates that can overcome the limitations of current influenza vaccines...

This $649,896 Project Grant award from the U.S. Department of Agriculture's Agriculture and Food Research Initiative (CFDA 10.310) aims to develop an mRNA vaccine against influenza A viruses (IAVs) that pose significant economic losses in livestock and pandemic threats to human populations. The award supports research to test an mRNA vaccine cocktail delivered via peptide-based cationic nanoparticles, targeting the HA globular head and conserved HA stalk domains to provide broad protection...

This $648,881 federal Project Grant award from the USDA National Institute of Food and Agriculture's Agriculture and Food Research Initiative (CFDA 10.310) supports the development of a universal mucosal vaccine to prevent influenza virus infections in dairy cows and reduce transmission between animals and humans. The University of Maryland, College Park is conducting research to engineer an Fc receptor-based nasal spray vaccine that can trigger long-lasting mucosal immunity in the respiratory...